# Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

> **NCT05028140** · PHASE3 · RECRUITING · sponsor: **EMS** · enrollment: 480 (estimated)

## Conditions studied

- Type II Diabetes

## Interventions

- **DRUG:** PIEMONTE
- **OTHER:** PIEMONTE PLACEBO
- **DRUG:** EMPAGLIFLOZIN
- **OTHER:** PLACEBO EMPAGLIFLOZIN
- **DRUG:** PIOGLITAZONE
- **OTHER:** PLACEBO PIOGLITAZONE

## Key facts

- **NCT ID:** NCT05028140
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2026-07
- **Final completion:** 2027-09
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028140, "Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05028140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*